100
Participants
Start Date
June 26, 2020
Primary Completion Date
August 25, 2025
Study Completion Date
August 25, 2025
Pembrolizumab
Administered via IV infusion at a specified dose on specified days
Quavonlimab
Administered via IV infusion at a specified dose on specified days
Vibostolimab
Administered via IV infusion at a specified dose on specified days
Lenvatinib
Administered via oral capsules at a specified dose on specified days
ATRA
Administered via oral capsules at a specified dose on specified days
CHUV Centre Hospitalier Universitaire Vaudois ( Site 1602), Lausanne
Hôpitaux Universitaires de Genève (HUG)-Oncology ( Site 1603), Geneva
Melanoma Institute Australia ( Site 1402), Wollstonecraft
Calvary Mater Newcastle-Medical Oncology ( Site 1404), Waratah
Tasman Oncology Research Pty Ltd ( Site 1403), Southport
CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE-Clinical Trials Unit ( Site 1865), Port Elizabeth
Fiona Stanley Hospital ( Site 1401), Murdoch
Universitaetsspital Zuerich ( Site 1601), Zuerich Flughafen
NYU Clinical Cancer Center ( Site 1002), New York
Hopital La Timone ( Site 1103), Marseille
University of Pennsylvania Abramson Cancer Center ( Site 1008), Philadelphia
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1399), Milan
Istituto Europeo di Oncologia ( Site 1301), Milan
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 1022), Baltimore
Inova Schar Cancer Institute ( Site 1011), Fairfax
Duke Cancer Institute ( Site 1005), Durham
Institut Claudius Regaud ( Site 1105), Toulouse
Hopital Saint Andre ( Site 1108), Bordeaux
Istituto Oncologico Veneto IRCCS ( Site 1355), Padua
West Cancer Center - East Campus ( Site 1014), Germantown
Martha Morehouse Tower ( Site 1020), Columbus
Policlinico Le Scotte - A.O. Senese ( Site 1377), Siena
Centre Hospitalier Lyon Sud ( Site 1102), Pierre-Bénite
A.P.H. Paris, Hopital Saint Louis ( Site 1107), Paris
University of Texas MD Anderson Cancer Center ( Site 1006), Houston
University of Colorado, Anschutz Cancer Pavilion ( Site 1012), Aurora
Istituto Nazionale Tumori Fondazione Pascale ( Site 1302), Napoli
The Angeles Clinic and Research Institute ( Site 1009), Los Angeles
UCLA Hematology & Oncology ( Site 1004), Los Angeles
Providence Saint John's Health Center ( Site 1010), Santa Monica
Gustave Roussy ( Site 1101), Villejuif
Oregon Health & Science University ( Site 1013), Portland
HaEmek Medical Center ( Site 1703), Afula
Rambam Health Care Campus-Oncology ( Site 1704), Haifa
Chaim Sheba Medical Center ( Site 1701), Ramat Gan
Hadassah Ein Karem Jerusalem ( Site 1702), Jerusalem
Merck Sharp & Dohme LLC
INDUSTRY